Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- RANKL and OPG activity is regulated by injury size in networks of osteocyte-like cells.Bone. 2011; 48: 182-188
- What is the normal rate of bone remodeling?.Bone. 2004; 35: 1-3
- Establishing a reference interval for bone turnover markers in 637 healthy, young, premenopausal women from United Kingdom, France, Belgium, and the United States.J Bone Miner Res. 2009; 24: 389-397
- Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females.J Bone Miner Res. 1988; 3: 133-144
- Biochemical indices of bone turnover and the assessment of fracture probability.Osteoporos Int. 2002; 13: 523-526
- Diagnosis, prophylaxis and treatment of osteoporosis.Am J Med. 1993; 94: 646-650
- Assessment of fracture risk and its application to screening for postmenopausal osteoporosis.(Technical report – series n 843) WHO, Geneva (Switzerland)1994
- Practical guide for the use of bone mineral measurements in the assessment of treatment of osteoporosis: a position paper of the European Foundation for Osteoporosis and Bone Disease. On behalf of the Scientific Advisory Board and the Board of National Societies.Osteoporos Int. 1996; 6: 256-261
- FRAX™ and the assessment of fracture probability in men and women from the UK.Osteoporos Int. 2008; 19: 385-397
- Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.Br Med J. 1996; 312: 1254-1259
- The effects of a FRAX® revision for the USA.Osteoporos Int. 2010; 21: 35-40
- Guidance for the adjustment of FRAX according to the dose of glucocorticoids.Osteoporos Int. 2011; 22: 809-816
- Effect of risedronate on the risk of hip fracture in elderly women. For the Hip Intervention Program Study Group.N Engl J Med. 2001; 344: 333-340
- Bone mineral density thresholds for pharmacological intervention to prevent fractures.Arch Intern Med. 2004; 164: 1108-1112
- Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.J Bone Miner Res. 1996; 11: 337-349
- Seasonal variation in bone mineral content in postmenopausal women.in: Dequeker J. Geusens P. Wahner H.W. Bone mineral measurement by photon absorptiometry. Leuven University Press, Leuven (Belgium)1988: 225
- Seasonal changes in calciotropic hormones, bone markers, and bone mineral density in elderly women.J Clin Endocrinol Metab. 2002; 87: 2024-2032
- Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women: a randomized placebo-controlled trial.J Clin Endocrinol Metab. 1998; 83: 3817-3825
- Changes in biochemical indexes of bone metabolism and bone mineral density after 12-mo dietary intervention program: the postmenopausal health study.Am J Clin Nutr. 2007; 86: 781-789
- Inhibition of none turnover by milk intake in postmenopausal women.Br J Nutr. 2008; 100: 866-874
- Effect of potassium citrate supplementation or increased fruit and vegetable intake on bone metabolism in healthy postmenopausal women: a randomized controlled trial.Am J Clin Nutr. 2008; 88: 465-474
- Nutritional associations with bone loss during the menopausal transition: evidence of a beneficial effect of calcium, alcohol, and fruit and vegetable nutrients and of a detrimental effect of fatty acids.Am J Clin Nutr. 2004; 79: 155-165
- Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women.J Bone Miner Res. 2007; 22: 1155-1164
- The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.J Bone Miner Res. 1999; 14: 1583-1595
- Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter (EPIDOS study group).J Clin Endocrinol Metab. 1996; 81: 1129-1133
- Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study.J Bone Miner Res. 1996; 11: 1531-1538
- Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.J Bone Miner Res. 2000; 15: 1526-1536
- Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years.J Bone Miner Res. 2010; 25: 393-403
- Identification of osteopenic women at high risk of fracture: the OFELY study.J Bone Miner Res. 2005; 20: 1813-1819
- Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study.Osteoporos Int. 2000; 11: 76-82
- Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: a three year follow-up study.Bone. 1996; 5: 487-488
- Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study.J Clin Endocrinol Metab. 1997; 82: 719-724
- Serum type 1 collagen breakdown products (serum CTX) predicts hip fracture in elderly women: the EPIDOS study.Bone. 2000; 27: 283-286
- High bone turnover is associated with accelerated bone loss but not with increased fracture risk in men aged 50 and over: the prospective MINOS study.Ann Rheum Dis. 2008; 67: 1249-1255
- Association between bone turnover rate and bone microarchitecture in men: the STRAMBO study.J Bone Miner Res. 2010; 25: 2313-2323
- Bone density and markers of bone remodeling in type 1 male diabetic patients.Diabetes Metab. 2006; 32: 453-458
- Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk.J Clin Endocrinol Metab. 2008; 93: 2622-2632
- Biochemical markers of bone turnover reflect femoral bone loss in elderly women.Calcif Tissue Int. 1996; 59: 328-333
- Rapid bone loss is associated with increased levels of biochemical markers.J Bone Miner Res. 1998; 13: 297-302
- Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study.J Bone Miner Res. 1999; 14: 1614-1621
- Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study.Br Med J. 1991; 303: 961-964
- Prediction of bone loss using biochemical markers of bone turnover.Osteoporos Int. 2007; 18: 1297-1305
- Biochemical markers as predictors of rates of bone loss after menopause.J Bone Miner Res. 2000; 15: 1398-1404
- Use of pamidronate in chronic and acute bone loss conditions.Medicina. 1997; 57: 101-108
- Pretreatment levels of bone turnover and the fracture efficacy of alendronate: the fracture intervention trial.J Bone Miner Res. 2006; 21: 292-299
- Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal women treated with risedronate.J Bone Miner Res. 2004; 19: 323-329
- Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial.J Bone Miner Res. 2004; 19: 1250-1258
- Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy.Osteoporos Int. 2007; 18: 201-210
- Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.J Bone Miner Res. 2005; 20: 962-970
- Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.Bone. 2010; 46: 929-934
- Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.Bone. 2010; 46: 935-939
- Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis.J Rheumatol. 2010; 37: 141-148
- Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial.JAMA. 1999; 282: 1344-1352
- Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.J Bone Miner Res. 2003; 18: 1051-1056
- Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study.Osteoporos Int. 2004; 15: 792-798
- Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.Am J Med. 2002; 112: 281-289
- Ten years’ experience with alendronate for osteoporosis in postmenopausal women.N Engl J Med. 2004; 350: 1189-1199
- Rapid and robust response of biochemical markers of bone formation to teriparatide therapy.Bone. 2009; 45: 1053-1058
- Variability in the measured response of bone to teriparatide.Osteoporos Int. 2010; 22: 1703-1708
- Effects of teriparatide [recombinant human parathyroid hormone (1–34)] on cortical bone in postmenopausal women with osteoporosis.J Bone Miner Res. 2003; 18: 539-543
- The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.N Engl J Med. 2003; 349: 1207-1215
- Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis.J Clin Endocrinol Metab. 2010; 95: 1838-1845
- The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.N Engl J Med. 2004; 350: 459-468
- Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years.Osteoporos Int. 2010; 21: 1031-1036
- The effect of PTH (1–84) or strontium ranelate on bone formation markers in postmenopausal women with primary osteoporosis: results of a randomized, open-label clinical trial.Osteoporos Int. 2010; ([Epub ahead of print])
- Six and twelve month change in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis.Osteoporos Int. 2001; 12: 922-930
- Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.Osteoporos Int. 2010; 21: 233-241
- Bisphosphonate therapy for the treatment of postmenopausal osteoporosis.Aging Health. 2005; 1: 1-16
- Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.J Bone Miner Res. 2011; 26: 530-537
- Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.J Bone Miner Res. 2009; 24: 1544-1551
- Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N Engl J Med. 2007; 356: 1809-1822
- Denosumab for prevention of fractures in postmenopausal women with osteoporosis.N Engl J Med. 2009; 361: 756-765
- Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club.Int J Clin Pract. 2009; 63: 19-26
- Adherence to treatment of primary osteoporosis and its association to fractures – The Swedish Adherence Register Analysis (SARA).Osteoporos Int. 2011; ([Epub ahead of print])
- Effects of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.J Clin Endocrinol Metab. 2007; 92: 1296-1304
- Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.JAMA. 2006; 296: 2927-2938
- Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.Osteoporos Int. 2008; 19: 1613-1620
- The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women.J Clin Endocrinol Metab. 2009; 94: 538-544
- Atypical fractures as a potential complication of long-term bisphosphonate therapy.JAMA. 2010; 304: 1480-1484
- Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.J Oral Maxillofac Surg. 2007; 65: 2397-2410
- The WHO absolute fracture risk models (FRAX): do clinical risk factors improve fracture prediction in older women without osteoporosis?.J Bone Miner Res. 2011; ([Epub ahead of print])
Article info
Footnotes
The authors have nothing to disclose.
Identification
Copyright
© 2011 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
